Orasis Pharmaceuticals Appoints Julie Speed as Senior Vice President, Head of Strategy and Marketing to Lead Commercial Growth Plan
04 oct. 2021 08h00 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Orasis Pharmaceuticals Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth
26 avr. 2021 08h00 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Orasis Pharmaceuticals Announces Initiation of Phase 3 Clinical Studies of Novel Eye Drop Candidate for the Treatment of Presbyopia
28 oct. 2020 09h15 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the...
Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia
10 sept. 2020 09h30 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment...
Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopia
10 oct. 2019 09h30 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
27 mars 2019 09h14 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, March 27, 2019 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
27 nov. 2018 08h00 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a clinical stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors
22 oct. 2018 08h00 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD. a clinical-stage pharmaceutical company developing a corrective eye drop for the treatment of presbyopia as an...
Orasis Pharmaceuticals Closes $13 Million Series B Financing
05 juin 2018 09h30 HE
|
Orasis Pharmaceuticals
HERZLIYA, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- Orasis Pharmaceuticals LTD., a privately-held, clinical-stage pharmaceutical company focused on developing an innovative eye drop for the...